Sredniawa Beata, Lenarczyk Radoslaw, Kowalski Oskar, Pruszkowska-Skrzep Patrycja, Kowalczyk Jacek, Musialik-Lydka Agata, Cebula Sylwia, Kalarus Zbigniew
First Department of Cardiology, Medical University of Silesia, Silesian Center for Heart Diseases, Szpitalna 2 Street, 41-800 Zabrze, Poland.
Europace. 2009 Jan;11(1):106-14. doi: 10.1093/europace/eun310. Epub 2008 Nov 12.
To assess the impact of baseline apnoea-hypopnoea index (AHI) on mid-term outcome and its change after 6 months of cardiac resynchronization therapy (CRT) on remote outcome.
In 71 patients with CRT devices, Holter-derived AHI was assessed before and 6 months after the procedure. Baseline AHI >20 was considered abnormal. After 6 months of CRT, a 50% decrease of baseline AHI was considered significant and stratified patients into AHI dippers and non-dippers, except those who preserved normal AHI. Prognostic value of baseline AHI and its change were assessed in relation to mortality and major cardiac events (MACE). More patients with an abnormal AHI died during 6 months follow-up (P = 0.02), especially due to sudden cardiac death. MACE-rate was insignificantly higher in abnormal AHI patients. Significantly higher mortality (P = 0.001), especially due to heart failure progression and higher MACE-rate (P < 0.001) during further observation were observed in AHI non-dippers. In multivariate analysis, the absence of AHI reduction was an independent predictor of mortality [hazard ratio (HR) 6.56, P = 0.015)] and MACE (HR 6.05, P = 0.002).
Abnormal baseline AHI identifies patients prone to death during mid-term observation. Lack of AHI reduction after 6 months of CRT is an independent risk factor of death and MACE during further follow-up.
评估基线呼吸暂停低通气指数(AHI)对中期预后的影响,以及心脏再同步治疗(CRT)6个月后其变化对远期预后的影响。
对71例植入CRT设备的患者,在手术前及术后6个月评估动态心电图得出的AHI。基线AHI>20被认为异常。CRT治疗6个月后,基线AHI降低50%被认为有显著意义,并将患者分为AHI下降者和非下降者,但不包括那些AHI保持正常的患者。评估基线AHI及其变化与死亡率和主要心脏事件(MACE)的预后价值。更多AHI异常的患者在6个月随访期间死亡(P = 0.02),尤其是心源性猝死。AHI异常患者的MACE发生率略高。在进一步观察中,AHI非下降者的死亡率显著更高(P = 0.001),尤其是因心力衰竭进展导致的死亡率更高,MACE发生率也更高(P < 0.001)。多因素分析中,AHI未降低是死亡率[风险比(HR)6.56,P = 0.015]和MACE(HR 6.05,P = 0.002)的独立预测因素。
基线AHI异常可识别出在中期观察期间易死亡的患者。CRT治疗6个月后AHI未降低是进一步随访期间死亡和MACE的独立危险因素。